877-272-6226
2017年，胰腺癌行动网络（邦山）获奖six new grantsto advance novel treatment options for patients with pancreatic cancer, including two first-time precision medicine targeted grants. These grants were part of the 17 total2017 research grants潘山最近在全国各地的12个机构授予21名研究人员。
How are new treatments brought to patients?
作为美国癌症相关死亡的第三个主要原因，胰腺癌迫切需要更好的患者治疗方案。为了给患者带来新的治疗，首先通过研究人员在实验室中鉴定一种新化合物，并经历严格的临床前测试（癌细胞和动物模型中）。这项重要研究评估了化合物的生物，化学和毒理学特性。最终，研究有助于科学家知道化合物是否具有可能改善患者结果的抗癌活动。一旦研究人员聚集了稳健的证据，治疗可以继续在人类中研究临床试验。
With PanCAN’s goal to double survival by 2020, the organization supports preclinical research of promising treatment ideas through ourResearch Grants Program. Some of the novel approaches being explored by this year’s new grantees include treatments aiming to disrupt pancreatic cancer’s dense stroma environment and immunotherapies (treatments that boost the body’s own immune system to fight cancer).
探索我们正在推进的新型研究，以改善患者的治疗方法：
- Multiplex tissue-based assays and analytical tools for pancreatic cancer (Gregory Beatty, MD, PhD, at University of Pennsylvania)
- Disrupting Tissue Factor-beta1 integrin axis in pancreatic cancer (Vladimir Bogdanov, PhD, and co-PI Syed Arif Ahmad, MD，在辛辛那提大学）
- Therapeutic vulnerabilities of mesenchymal pancreatic cancer cells (Giulio Draetta, MD, PhD, at MD Anderson Cancer Center)
- Combining stromal disruption and relief of immune suppression to treat PDA (Sunil Hingorani, MD, PhD, at Fred Hutchinson Cancer Research Center)
- 提高工程T细胞治疗对胰腺癌的疗效（Ingunn Stromnes, PhD，明尼苏达大学）
- Targeting cholinergic receptors to suppress pancreatic cancer (蒂莫西王，MD和Co-PiaPaul Oberstein，MD, at Columbia University)
Learn more about all our2017 grantees和今天送礼物to support critical research.
